To evaluate the role of CDK6 in this disease context, we analyzed RNA-Seq data of a previously published CML patient cohort, including CML patients in chronic phase (CP-CML), accelerated phase (AP-CML) and blast crisis (BC-CML) as well as in controls [45]. This evidence concerns the gene CDK6 and chronic myelogenous leukemia, BCR-ABL1 positive.